Latest News and Press Releases

Auron Therapeutics will participate in the 8th Annual Targeted Protein Degradation (TPD) & Induced Proximity Summit in Boston.

NEWTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory...

NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory...

NEWTON, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics,  a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory...

NEWTON, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory...

NEWTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory...

NEWTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory...

Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025 Series B Financing Funds AUTX-703 Development through Phase 1 Clinical...

Data demonstrate dose dependent survival advantage with AUTX-703 in primary patient-derived orthotopic AML model IND submissions on track for late 2024 NEWTON, Mass., Dec. 09, 2024 (GLOBE...

NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...